FIBROGEN INC - COMMON STOCK

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting

24 Apr 2024 16:02:00 By Nasdaq GlobeNewswire

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

02 Apr 2024 17:46:47 By Nasdaq GlobeNewswire

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

26 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

11 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

26 Feb 2024 16:06:00 By Nasdaq GlobeNewswire

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

26 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

20 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

05 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

25 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

09 Dec 2023 17:02:00 By Nasdaq GlobeNewswire

FibroGen Reports Third Quarter 2023 Financial Results

06 Nov 2023 16:01:00 By Nasdaq GlobeNewswire

FibroGen to Report Third Quarter 2023 Financial Results

23 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy

29 Aug 2023 16:15:00 By Nasdaq GlobeNewswire

FibroGen Reports Second Quarter 2023 Financial Results

07 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis

26 Jun 2023 07:04:00 By Nasdaq GlobeNewswire

FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy

07 Jun 2023 06:55:00 By Nasdaq GlobeNewswire

FibroGen to Present at Jefferies Global Healthcare Conference

06 Jun 2023 16:01:00 By Nasdaq GlobeNewswire

FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

18 May 2023 07:30:00 By Nasdaq GlobeNewswire

FibroGen Reports First Quarter 2023 Financial Results

08 May 2023 16:01:00 By Nasdaq GlobeNewswire

FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics

08 May 2023 16:00:00 By Nasdaq GlobeNewswire